文献速递前列腺癌

前列腺切除术后调强放疗的患者报告结局与晚期毒性

Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy.
PubMed 文献 · Eur Urol · 2019-05-19

这项前瞻性队列研究纳入2007至2015年在一家学术机构接受前列腺切除术后调强放疗的199例连续前列腺癌患者,中位随访33个月,采用EPIC-26量表评估生活质量,并按RTOG/CTCAE分级记录毒性。总体泌尿、肠道、性功能及泌尿刺激/梗阻评分均未低于最小临床重要差异,4年无≥2级泌尿和胃肠道毒性率分别为94%和95%。

要点

  • 前列腺切除术后调强放疗后总体泌尿、肠道、性功能及泌尿刺激/梗阻评分均未低于最小临床重要差异。
  • 4年无≥2级泌尿毒性和胃肠道毒性率分别为94%和95%。
  • 较长的放疗等待时间、较高BMI、较大年龄、激素治疗、总剂量、吸烟史及较高膀胱V70Gy与更差的生活质量或毒性相关。

核心结论

  • 前列腺切除术后放疗后长期生活质量和晚期毒性表现良好。
  • 可识别的临床和剂量学危险因素可能指导决策以优化泌尿、性和肠道功能。

研究设计与样本

  • 前瞻性队列研究,纳入2007至2015年在一家学术机构接受前列腺切除术后调强放疗的199例连续前列腺癌男性患者。
  • 治疗照射前列腺床(中位68Gy),±盆腔淋巴引流区(65%的患者,中位50.4Gy),每日图像引导。
  • 132例(66%)男性同时接受雄激素剥夺治疗,中位疗程4个月。
  • 采用EPIC-26生活质量量表前瞻性评估,每次随访时按RTOG/CTCAE标准评定毒性分级。
  • 中位随访33个月。

主要发现

  • 总体泌尿功能、肠道功能、性功能和泌尿刺激/梗阻评分从未低于最小临床重要差异。
  • 在放疗后至84个月的特定时间点,8%至18%的男性经历小的多领域(1倍最小临床重要差异)下降,0至8%经历中等多领域(2倍最小临床重要差异)下降。
  • 4年无≥2级泌尿生殖毒性和胃肠道毒性的比率分别为94%和95%。

关键数值与推荐

  • 与更差生活质量或毒性相关的因素包括:较长的至放疗时间(泌尿刺激/梗阻和泌尿功能)、较高BMI(泌尿功能、肠道功能和晚期胃肠道毒性)、较大年龄(肠道功能、性功能和晚期泌尿生殖毒性)。
  • 激素治疗(性功能)、总剂量(晚期胃肠道毒性)、吸烟史(肠道功能)和较高膀胱V70Gy(泌尿刺激/梗阻、泌尿功能和晚期泌尿生殖毒性)也与更差结局相关。

临床怎么用

  • 作者认为,可识别的临床和剂量学危险因素可能指导决策以优化泌尿、性和肠道功能。
  • 作者指出,研究结果可为计划接受该放疗的患者提供预期症状的指导,并帮助医生适当咨询患者及调整某些临床和放疗相关危险因素以优化生活质量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited long-term data characterize patient-reported quality of life (QOL) following postprostatectomy intensity-modulated radiation therapy (PPRT), and predictors of decline are poorly defined. OBJECTIVE: To identify modifiable dosimetric and clinical risk factors impacting QOL and late toxicity following PPRT. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study of consecutive men with prostate cancer who received PPRT between 2007 and 2015 at a single academic institution. INTERVENTION: Patients were prospectively evaluated using the Expanded Prostate Cancer Index Composite (EPIC-26) QOL instrument. Radiation Therapy Oncology Group/Common Toxicity Criteria for Adverse Events toxicity grades were assigned at every follow-up visit. Treatment was delivered to the prostate bed (median 68Gy)±pelvic lymphatics (65%, median 50.4Gy) with daily image guidance. Androgen deprivation therapy was concomitantly administered to 132 (66%) men for a median of 4mo. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Changes were deemed relevant if they exceeded the minimally clinically important difference (MCID), as calculated by a distribution-based method. Generalized estimating equation models and Cox regression were used for QOL and late toxicity univariate and multivariable analysis. RESULTS AND LIMITATIONS: Overall, 199 men were identified with a median follow-up of 33mo. Overall urinary function (UF), bowel function (BF), sexual function (SF), and urinary irritation/obstruction (UI/UO) scores were never lower than the MCID. Between 8% and 18% of men experienced a small multidomain (1× MCID) decline, and 0-8% experienced a moderate multidomain decline (2× MCID) at a given time point up to 84mo after PPRT. The rates of freedom from grade 2 or higher (Gr2+) genitourinary (GU) and gastrointestinal (GI) toxicity were 94% and 95%, respectively, at 4yr. Factors associated with worse QOL or toxicity included longer time to PPRT (UC and UF), higher BMI (UF, BF, and late GI toxicity), older age (BF, SF, and late GU toxicity); hormone therapy (SF), total dose (late GI toxicity), tobacco history (BF), and higher bladder V70Gy (UC, UF, and late GU toxicity). CONCLUSIONS: Long-term QOL and late toxicity are favorable following postprostatectomy radiation therapy. Identifiable clinical and dosimetric risk factors may guide decision making to optimize urinary, sexual, and bowel function. PATIENT SUMMARY: The following study provides a detailed report of favorable patient-reported quality of life and late side-effect profiles of radiation therapy following surgery for localized prostate cancer. Our findings provide patients guidance on what symptoms to expect if they are planning to undergo radiation therapy in this setting. It also allows physicians to counsel patients appropriately, and modify certain clinical and radiation-related risk factors to optimize quality of life.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Akthar AS, Liao C, Eggener SE, et al. Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy. Eur Urol. 2019. PMID: 31113644. doi:10.1016/j.eururo.2019.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。